Amgen's Obesity Drug Shows Weight Loss Maintenance

Amgen is highly optimistic about its experimental obesity drug, MariTide, preparing to release new data from a mid-stage trial extension. This phase is specifically designed to assess the drug's efficacy in helping patients sustain weight loss over time. The company's research chief highlighted their leading position in developing less frequent dosing for such medications.

Results from a Phase 2 trial extension are set to be unveiled, alongside findings from a separate trial targeting diabetes patients. Earlier reports indicated MariTide could help patients shed up to 20% of their body weight. However, gastrointestinal side effects were noted, prompting plans for future trials to begin with lower, gradually increasing doses.

Amgen's MariTide employs a unique strategy, linking an antibody to peptides that activate the GLP-1 receptor while simultaneously blocking the GIP receptor. This approach differentiates it from weekly injections like Wegovy and Zepbound, which target GLP-1 or both GLP-1 and GIP. The company is currently undertaking extensive Phase 3 trials to further evaluate MariTide's potential.